Medios AG (DE:ILM1)
XETRA:ILM1
Want to see DE:ILM1 full AI Analyst Report?
Top Page
Medios AG
(XETRA:ILM1)
Select Model
Select Model
Rating:56Neutral
Price Target:
€12.00
▼(-7.83% Downside)
Action:DowngradedDate:03/27/26
The score is primarily driven by moderate financial performance—strong revenue scaling but significant margin compression, thin profitability, and volatile free cash flow. Technicals are a major drag with a clear downtrend versus all key moving averages and negative MACD. Valuation is middling with a ~23.6 P/E and no dividend support.
Positive Factors
Specialty pharma & compounding focus
Medios' core focus on patient‑individual therapies and specialty pharmaceutical distribution is a durable business model. The operational requirements (compounding, sterile prep, cold-chain logistics) create higher switching costs and service stickiness with pharmacies and clinics, supporting recurring revenue and differentiated capabilities over multiple months.
Negative Factors
Sharp margin compression
A collapse in gross margin to ~4.4% and net margin below 1% materially reduces the firm's operating buffer. Such thin profitability leaves limited room to absorb input cost swings, pricing pressure or reimbursement changes, increasing structural earnings sensitivity and constraining reinvestment capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty pharma & compounding focus
Medios' core focus on patient‑individual therapies and specialty pharmaceutical distribution is a durable business model. The operational requirements (compounding, sterile prep, cold-chain logistics) create higher switching costs and service stickiness with pharmacies and clinics, supporting recurring revenue and differentiated capabilities over multiple months.
Read all positive factors
Medios AG (ILM1) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€332.08M
Dividend YieldN/A
Average Volume (3M)45.28K
Price to Earnings (P/E)23.6
Beta (1Y)0.81
Revenue Growth9.27%
EPS Growth65.65%
CountryDE
Employees472
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.19
Shares Outstanding25,505,724
10 Day Avg. Volume55,289
30 Day Avg. Volume45,276
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)0.71
Price to Sales (P/S)0.17
P/FCF Ratio9.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.33Price Target Upside79.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.18
Revenue Forecast (FY)€2.09B
Medios AG Business Overview & Revenue Model
Company Description
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products ...
How the Company Makes Money
Medios AG generates revenue primarily through (1) pharmaceutical compounding/manufacturing services and (2) wholesale distribution/trading of specialty pharmaceuticals. In its patient-individual therapies business, Medios earns income by preparing...
Medios AG Earnings Call Summary
Earnings Call Date:Nov 12, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.Positive Updates
Record Q3 Performance
The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.
Negative Updates
PST Segment Challenges
PST gross profit decreased due to deconsolidation of Kölsche Blister, regulatory headwinds, and increased performance-based payments.
Read all updates
Q3-2024 Updates
Positive
Negative
Record Q3 Performance
The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.
Read all positive updates
Company Guidance
During the Q3 2024 earnings call for Medios AG, the company provided several key financial metrics and guidance highlights. The company achieved a revenue growth of more than 4% to EUR 1.4 billion for the first nine months of 2024, with a significant EBITDA pre increase of over 20% to EUR 55.8 million. The EBITDA pre margin reached the 5% mark for the first time, driven by strong performances in the PST and Ceban segments. Operational cash flow more than doubled to EUR 27.6 million, and the company confirmed its guidance for 2024, anticipating full-year revenues between EUR 1.9 billion and EUR 2.1 billion and an EBITDA pre in the range of EUR 82 million to EUR 91 million. The company also noted inorganic growth due to the acquisition of Ceban, contributing EUR 47.3 million in revenue and EUR 9.8 million in EBITDA pre for the period June through October 2024. Additionally, Medios is focusing on strategic priorities, including expanding operations into other European countries and entering the production of advanced therapies, with a commitment to maintaining high-quality personalized medicines.Medios AG Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
68
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.08B | 1.88B | 1.78B | 1.61B | 1.36B |
| Gross Profit | 91.93M | 151.46M | 108.63M | 106.87M | 68.48M |
| EBITDA | 79.59M | 64.00M | 52.82M | 51.33M | 34.68M |
| Net Income | 15.37M | 12.55M | 18.81M | 18.33M | 7.40M |
Balance Sheet | |||||
| Total Assets | 903.04M | 934.36M | 594.75M | 575.96M | 524.14M |
| Cash, Cash Equivalents and Short-Term Investments | 81.84M | 106.00M | 71.04M | 79.21M | 168.43M |
| Total Debt | 188.89M | 238.37M | 17.15M | 17.63M | 49.71M |
| Total Liabilities | 388.82M | 424.17M | 125.95M | 127.91M | 129.98M |
| Stockholders Equity | 514.22M | 510.19M | 468.81M | 448.05M | 394.16M |
Cash Flow | |||||
| Free Cash Flow | 36.94M | 67.36M | 15.14M | 32.06M | 48.70M |
| Operating Cash Flow | 43.00M | 73.67M | 16.41M | 37.12M | 61.52M |
| Investing Cash Flow | -4.78M | -222.28M | -16.57M | -86.54M | 17.36M |
| Financing Cash Flow | -62.60M | 183.80M | -8.01M | -39.80M | 69.76M |
Medios AG Technical Analysis
Negative
13.02
Price Trends
14.87
Negative
14.78
Negative
14.14
Negative
Market Momentum
-0.53
Negative
42.92
Neutral
87.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ILM1, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 12.94, below the 50-day MA of 14.87, and below the 200-day MA of 14.14, indicating a neutral trend. The MACD of -0.53 indicates Negative momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 87.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:ILM1.
Medios AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €277.93M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
73 Outperform | €144.00M | 8.54 | 22.77% | ― | 0.21% | 7.53% | |
56 Neutral | €332.08M | 23.60 | 2.97% | ― | 9.27% | 65.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | €23.28M | -1.84 | 22.85% | ― | 6.87% | -94.85% |
* Healthcare Sector Average
DE:ILM1
Medios AG
13.00
1.32
11.30%
DE:MAK
MATERNUS-Kliniken AG
1.16
-0.07
-5.69%
DE:LIK
Limes Schlosskliniken AG
482.00
226.00
88.28%
DE:EIF
Eifelhoehen-Klinik AG
3.40
2.00
142.86%
DE:JTH0
Gesundheitswelt Chiemgau AG
12.00
-0.08
-0.66%
DE:M12
M1 Kliniken AG
15.00
-1.40
-8.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.